第三部分:临床前脓毒症研究最低质量标准(MQTiPSS)之液体复苏与抗菌治疗终点
2016年脓毒症与脓毒性休克管理国际指南将初始液体复苏和抗菌药物给药列为早期管理的关键步骤,但临床前脓毒症模型缺乏此类明确指南。2017年5月在维也纳召开的Wiggers-Bernard临床前脓毒症模型会议复习了2003至2012年间260篇高被引脓毒症模型论文,发现超过70%的实验未使用或未报告复苏和/或抗菌治疗。据此,会议为临床前脓毒症模型制定了一系列推荐与考虑,本第三部分详述液体复苏和抗菌治疗方面的推荐:除非研究本身涉及,否则推荐液体复苏;首选等渗晶体液;给药途径和时机应据模型调整,优先动态而非静态血流动力学监测;应考虑预设复苏终点并避免液体过负荷;推荐使用抗菌药物,选择和剂量据模型和病原体调整,理想情况下应贴近临床实践并考虑药代动力学及宿主因素。
要点
- 临床前脓毒症模型应实施液体复苏,除非研究本身涉及复苏;首选等渗晶体液。
- 液体复苏的给药途径和时机应据模型具体要求调整,优先采用动态而非静态血流动力学监测。
- 应考虑预设液体复苏终点并避免液体过负荷。
- 推荐临床前脓毒症研究使用抗菌药物,选择和剂量应据具体脓毒症模型和病原体调整。
- 抗菌药物给药应尽量贴近临床实践,考虑药物药代动力学、吸收分布清除变化及年龄、体重、合并症等宿主因素。
适用人群与场景
- 临床前脓毒症动物模型研究;不适用于人类脓毒症患者的直接临床决策。
处置流程与药物剂量
- 除非研究本身涉及,否则推荐在实验设置中进行液体复苏。
- 液体复苏首选等渗晶体液。
- 液体复苏的给药途径和时机应据模型具体要求调整,优先采用动态而非静态血流动力学监测。
- 应考虑预设液体复苏终点并避免液体过负荷。
- 推荐临床前脓毒症研究使用抗菌药物,选择和剂量应据具体脓毒症模型和病原体调整。
- 抗菌药物给药应尽量贴近临床实践,考虑药物药代动力学、吸收分布清除变化及年龄、体重、合并症等宿主因素。
研究设计与关键结果
- Wiggers-Bernard临床前脓毒症模型会议于2017年5月在维也纳召开,复习了2003至2012年间260篇高被引脓毒症模型论文。
- 复习显示超过70%的实验未使用或未报告复苏和/或抗菌治疗。
证据类型、等级与局限
- 证据类型:会议共识推荐(Wiggers-Bernard会议),基于对260篇高被引临床前脓毒症模型论文的复习。
- 推荐作为动物脓毒症模型的「最佳实践」实施。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些推荐与考虑应作为脓毒症动物模型的「最佳实践」实施,以改善临床前脓毒症研究中液体复苏和抗菌治疗报告与实施的不一致性。
指南或共识出处
- Wiggers-Bernard临床前脓毒症模型会议(2017年5月,维也纳);国际脓毒症与脓毒性休克管理指南:2016。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
As outlined in the "International Guidelines for Management of Sepsis and Septic Shock: 2016," initial fluid resuscitation and administration of antibiotics are key steps in the early management of sepsis and septic shock. However, such clear guidelines do not exist for preclinical sepsis models. To address these shortcomings, the Wiggers-Bernard conference on preclinical sepsis models was held in Vienna in May 2017. The participants reviewed 260 of the most highly cited papers between 2003 and 2012 that used sepsis models. The review demonstrated that over 70% of experiments either did not use or failed to report resuscitation and/or antibiotic treatment. This information served as the basis to create a series of recommendations and considerations for preclinical sepsis models; this Part III report details the recommendations for fluid resuscitation and antibiotic treatment that should be addressed in sepsis models. Similar to human sepsis, fluid resuscitation is recommended in the experimental setting unless part of the study. Iso-osmolar crystalloid solutions are preferred. The administration route and its timing should be adjusted to the specific requirements of the model with preference given to dynamic rather than static hemodynamic monitoring. Predefined endpoints for fluid resuscitation and avoidance of fluid overload should be considered. Preclinical sepsis studies display serious inconsistencies in the use of antimicrobial protocols. To remedy this, antimicrobials are recommended for preclinical studies, with choice and dose adjusted to the specific sepsis model and pathogen (s). Ideally, the administration of antimicrobials should closely mimic clinical practice, taking into account the drug's pharmacokinetic profile, alterations in absorption, distribution and clearance, and host factors such as age, weight, and comorbidities. These recommendations and considerations are proposed as "best practices" for animal models of sepsis that should be implemented.
参考来源
- Hellman J, Bahrami S, Boros M, et al. Part III: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Fluid Resuscitation and Antimicrobial Therapy Endpoints. Shock. 2019. PMID: 29923896. doi:10.1097/SHK.0000000000001209
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。